✦ LIBER ✦

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820

✍ Scribed by Ron J. Keizer; Miren K. Zamacona; Mendel Jansen; David Critchley; Jantien Wanders; Jos H. Beijnen; Jan H. M. Schellens; Alwin D. R. Huitema

Book ID: 118299033
Publisher: Springer US
Year: 2008
Tongue: English
Weight: 786 KB
Volume: 27
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-008-9164-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Current challenges for the early clinica

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents

✍ Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavi 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 148 KB

Clinical studies in the development of n

Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design

✍ Ferry A.L.M Eskens; Jaap Verweij 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Various new specifically targeted anticancer agents such as matrixmetalloproteinase inhibitors, angiogenesis inhibitors, farnesyl transferase inhibitors, and tyrosine kinase inhibitors have been developed in recent years. These agents exert antitumor activity through specific target inhibition, and

Evaluation of the toxic potentials of a

Evaluation of the toxic potentials of a new camptothecin anticancer agent CKD-602 on fertility and early embryonic development in rats

✍ Moon-Koo Chung; Sang-Seop Han; Jong-Choon Kim 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 315 KB

[AAPS Advances in the Pharmaceutical Sci

[AAPS Advances in the Pharmaceutical Sciences Series] Clinical Trial Simulations Volume 1 || Application of Pharmacokinetic–Pharmacodynamic Modeling and Simulation for Erythropoietic Stimulating Agents

✍ Kimko, Holly H. C.; Peck, Carl C. 📂 Article 📅 2010 🏛 Springer New York 🌐 English ⚖ 282 KB

There have been tremendous advancements in application of modeling and simulation (M&S) in drug development during the last decade. The pharmaceutical companies started to pay more attention to implement simulation exercises in drug development in order to achieve cost effectiveness. The Food and Dr

[AAPS Advances in the Pharmaceutical Sci

[AAPS Advances in the Pharmaceutical Sciences Series] Clinical Trial Simulations Volume 1 || The Application of Drug-Disease Models in the Development of Anti-Hyperglycemic Agents

✍ Kimko, Holly H. C.; Peck, Carl C. 📂 Article 📅 2010 🏛 Springer New York ⚖ 464 KB

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti